Clinical Trial Patient Recruitment (Non-squamous Non-small Cell Lung Cancer)

As the first hospital in China to clinically apply heavy ion systems and the only hospital worldwide operating two heavy ion systems simultaneously, we have accumulated over 2,010 treated cases across 50+ cancer types (including lung, pancreatic, and liver cancers) through five years of clinical practice. Our clinical effectiveness and patient survival rates meet international advanced standards.

Gansu Wuwei Cancer Hospital has achieved "Eight World/National Firsts":
✓ The only hospital globally operating two heavy ion treatment systems
✓ Performed the highest number of single-fraction treatments completed within one day worldwide
✓ Globally pioneered respiratory-gated heavy ion precision therapy
✓ First worldwide to develop bladder volume-controlled heavy ion therapy for bladder cancer
✓ First globally to implement surgical spacer placement for single-session heavy ion therapy
✓ China's first developer of 360° rotatable/elevating ion therapy chairs
✓ World's first to complete multiple cardiac tumor heavy ion treatments
✓ Globally the first to integrate heavy ion therapy with comprehensive whole-life-cycle health management

(Non-squamous NSCLC) Clinical Trial

Study Title

A Randomized, Controlled, Open-label Phase III Clinical Study of JMT101 Combined with Osimertinib versus Osimertinib Alone as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) with EGFR Sensitive Mutations

Inclusion Criteria

1. Voluntary written informed consent
2. Age ≥18 years, any gender
3. Newly diagnosed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IVA/IVB) non-squamous NSCLC unsuitable for radical surgery/radiotherapy
4. Central lab-confirmed EGFR sensitive mutations (Exon19 deletion/Exon21 L858R)

Exclusion Criteria

1. Prior EGFR-TKI treatment
2. Presence of meningeal metastases, spinal cord compression, or symptomatic/unstable brain metastases.ALK/ROS1/KRAS/BRAF/RET/MET/NTRK/HER2 mutations
3. Final eligibility determined by investigators per protocol

Contact Information

Coordinator:

Xi Caixia: +86-187-9359-8580

Tao Wenxue: +86-150-9563-2720

Address:

Department of Respiratory & Critical Care Medicine II,

Gansu Wuwei Cancer Hospital

Department Profile

The Department of Respiratory & Critical Care Medicine II at Gansu Wuwei Cancer Hospital is a provincial key discipline integrating clinical care, education, and research. Accredited as:
• National PCCM Level III Certified Unit
• China Lung Cancer Alliance Early Diagnosis/Treatment Center
• Pulmonary Nodule Early Diagnosis/Treatment Center

Team: 20 medical staff including:

• 1 Chief Physician
• 1 Associate Chief Physician
• 1 Associate Chief Nurse
• 3 Attending Physicians
• 2 Resident Physicians
• 2 Master's degree holders

Clinical Services:
Chronic bronchitis, pulmonary infections, COPD, cor pulmonale, asthma, bronchiectasis, pulmonary embolism, pneumothorax, pleural effusion, respiratory failure, hemoptysis, lung malignancies, etc.

Advanced Technologies:
• Painless bronchoscopy
• EBUS-guided procedures
• Rigid bronchoscopy
• Medical thoracoscopy
• CT-guided biopsy
• RF ablation/particle implantation
• Genetic testing/molecular diagnostics
• AI-assisted pulmonary nodule analysis

Location:
Department of Respiratory & Critical Care Medicine II

• Clinic: Room 309, Outpatient Building
• Inpatient: 5F, Central Hospital AreaTel: Outpatient 0935-6988532 / Inpatient 0935-6988606